SCHEMBL3923974

SCHEMBL3923974

CCCS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)C=C(CC(=O)OCC)N2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.41
AURKB Q96GD4 4/20 0.37
PLK4 O00444 3/20 0.37
DAPK3 O43293 3/20 0.37
JAK2 O60674 3/20 0.37
CDK1 P06493 3/20 0.37
RPS6KB1 P23443 3/20 0.37
CDK2 P24941 3/20 0.37
TYK2 P29597 3/20 0.37
CLK2 P49760 3/20 0.37
JAK3 P52333 3/20 0.37
LIMK1 P53667 3/20 0.37
CDK5 Q00535 3/20 0.37
DYRK1A Q13627 3/20 0.37
PKN2 Q16513 3/20 0.37
HIPK4 Q8NE63 3/20 0.37
CLK4 Q9HAZ1 3/20 0.37
STK17A Q9UEE5 3/20 0.37
AURKA O14965 3/20 0.37
MAPK13 O15264 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924187 0.93 HPGD (0.43) AURKBPLK4DAPK3JAK2CDK1
SCHEMBL394707 0.89 HPGD (0.43) AURKBAURKAMAPK1HPGDKDM4E
SCHEMBL3925098 0.84 BRD4 (0.38) BRD4JAK1ALDH1A1CYP17A1AAK1
SCHEMBL3920426 0.84 MAPT (0.44) BRD4AURKBAURKAKDM4EALDH1A1
SCHEMBL3926561 0.83 EGFR (0.35) HPGDKDM4EALDH1A1LMNATSHR
SCHEMBL3917990 0.80 ALDH1A1 (0.45) HPGDALDH1A1LMNATSHRHSD17B10
SCHEMBL13938254 0.79 CA12 (0.40) HPGDKDM4EALDH1A1LMNATSHR
SCHEMBL13686400 0.77 TNF (0.38) MAPK1HPGDKDM4EALDH1A1LMNA
SCHEMBL14198298 0.76 GAA (0.35) KDM4EALDH1A1LMNATSHRHSD17B10
SCHEMBL4894923 0.74 CYP1A2 (0.42) MAPK1ALDH1A1LMNATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786807-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2009-07-29 EP disclosed
US-7479489-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2009-01-20 US disclosed
US-20060040927-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040927-A1 Heterocyclic antiviral compounds HAVCR2, POLR1A, HCCS BRD4 1905/4885AURKB 2006/4885PLK4 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.